Introduction
Despite the evidence supporting the use of intravenous Magnesium Sulfate
(MS) in acute asthma; this drug continues being considered as the second
line in pediatric acute asthma exacerbations. This study aimed to
evaluate the cost-effectiveness of the MS in acute asthma.